Stocks · News reference

8-K filing — Cocrystal Pharma, Inc. (COCP)

Jul 17, 2026, 12:00 PMSEC EDGAR

Filed: 2026-07-17 AccNo: 0001493152-26-033662 Size: 210 KB Item 5.07: Submission of Matters to a Vote of Security Holders

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 18, 2026, 8:30 PMSEC EDGAR
8-K filing — Cocrystal Pharma, Inc. (COCP)
Filed: 2026-08-18 AccNo: 0001493152-26-039023 Size: 201 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgar
COCP
BenzingaAug 13, 2026, 12:23 PMBenzinga Newsdesk
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of $(0.20) per share from
Read original at benzinga
COCP
BenzingaAug 3, 2026, 2:22 PMBenzinga Newsdesk
Cocrystal Pharma shares are trading higher after the company announced a $5 million private placement with OPKO Health.
Read original at benzinga
COCP
BenzingaAug 3, 2026, 11:01 AMBenzinga Newsdesk
Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1b Data
Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP)
Read original at benzinga
COCP OPK